Divi's Laboratories Ltd. Share Price

Overview

Divi's Laboratories Ltd. share price is currently ₹9,224.07, up by ₹137.91 (1.52%) from its previous closing price of ₹9,086.16. The share price has gained 8.5% over the past month and gained 55.62% over the past year. The stock's 52-week low and high are ₹5,528.30 and ₹9,530.67, respectively. Divi's Laboratories Ltd. has a market capitalisation of ₹ 2,50,000.00 Cr. The share price was last updated on 17 Sep 2026, 03:59 PM IST.

Divi's Laboratories Ltd.
Divi's Laboratories Ltd.
DIVISLAB
 0.00
 137.91
1.52%
Healthcare
 0.00(%)1D

Updated: 17 Sep 2026, 03:59:28 pm IST

Market Data

Open Price

 9,056.85

Prev. Close

 9,086.16
 9,034.03

Day Low

 9,272.77

Day High

 5,528.30

52 Week Low

 9,530.67

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

83.57

Sector PE

44.64

PB Ratio

14.58

Sector PB

5.99

EPS

110.38

Dividend Yield

0.50

Today's Volume

502.375 K

5 Day Avg. Volume

528.163 K

PEG Ratio

4.86

Market Cap.

₹ 2,50,000.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 1500% at ₹30/Share
24-Jul-202624-Jul-2026
DividendsFinal Dividend of 1500% at ₹30/Share
25-Jul-202525-Jul-2025

Mutual Fund Ownership

Mutual Fund Holder
Jul 26
Shares held
Aug 26
Shares held
SBI Large Cap Fund - Regular Plan - Growth20.32 Lac
20.32 Lac
no change
SBI Aggressive Hybrid Fund - Regular Plan - IDCW-
19.00 Lac
(100%)
HDFC Flexi Cap Fund - Growth18.94 Lac
18.94 Lac
no change
SBI Focused Fund - Regular Plan - Growth15.70 Lac
15.70 Lac
no change
Axis ELSS - Tax Saver Fund - Regular Plan - Growth-
9.36 Lac
(100%)

About Divi's Laboratories Ltd. 👋

Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company's products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Quetiapine Fumarate, Naproxen Sodium, Olmesartan, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, and others. In addition to generics, the Company, through its custom synthesis, supports innovator pharma companies. It is engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company's subsidiaries include Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Nikita (SEBI RA)

Nikita (SEBI RA)

15 Sep • 1:06 PM · SEBI-Registered Analyst

“Why No-Trade Can Be a Smart Decision” .

Trading is not about finding an opportunity in every market condition. Sometimes price action remains unclear, volatility becomes unpredictable or the risk-to-reward relationship does not justify taking a position. In such situations, staying out can be a disciplined trading decision. A good setup should provide a clear reason for entry, a logical point where the idea becomes invalid and sufficient potential reward for the risk being taken. When these conditions are missing, forcing a trade can increase unnecessary exposure. Experienced traders understand that capital preservation is part of long-term performance. Waiting for better conditions allows traders to remain prepared when a higher-quality opportunity eventually appears. Learning: Not taking a trade is also a decision, especially when the setup does not offer a clear advantage.

DIVISLAB

See More
Jeet B Bhayani (SEBI RA)

Jeet B Bhayani (SEBI RA)

12 Sep • 7:53 PM · SEBI-Registered Analyst

Bharat Health Expo 2026: Pharma & Supply Chain

Speaking at the Bharat Health Global Expo 2026 in New Delhi, Union Minister of Commerce and Industry Piyush Goyal called for India to transform its pharmaceutical leadership by moving beyond generic drugs toward research, innovation, and resilient, globally integrated healthcare supply chains. Joined by Minister of State Jitin Prasada and Commerce Secretary Rajesh Agarwal, Mr. Goyal stressed the need to secure domestic supply chains for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), while urging Indian companies to invest in overseas markets for localized value addition and last-mile distribution. To accelerate this transition, he advocated for heightened focus on biosimilars, novel molecules, and biotechnology—supported by the Research and Development Innovation Fund—alongside regulatory alignment with developed markets to attract foreign direct investment. Highlighting industrial infrastructure, Mr. Goyal pointed to ongoing bulk drug park developments in Andhra Pradesh, Gujarat, and Himachal Pradesh, as well as plans for 100 plug-and-play industrial parks tailored for the healthcare and pharmaceutical sectors. He also urged a mission-mode strategy to capture the nearly ₹76,352 crore ($8 billion) medical value travel market. Emphasizing trade expansion, the Minister contrasted India's pre-2014 Free Trade Agreements (FTAs)—which covered a combined GDP of ₹954.40 lakh crore ($10 trillion)—with nine recently concluded FTAs unlocking access to ₹5,726.40 lakh crore ($60 trillion) in global GDP. He noted that active negotiations for 8 to 10 additional trade deals aim to provide Indian exporters access to 75% of total global trade.

DIVISLAB

See More
Shaly Gupta

Shaly Gupta

8 Sep • 1:19 PM · SEBI-Registered Analyst

Divi’s Laboratories (DIVISLAB) has delivered a very strong

DIVISLAB
Divi’s Laboratories (DIVISLAB) has delivered a very strong Q1 FY27. Revenue from operations increased 27.8% YoY to ₹3,080 crore, while consolidated PAT jumped 65.5% to ₹902 crore. Operating profitability improved sharply, with operating profit rising about 83% YoY, indicating strong operating leverage and better margins. The major positive is the company's strong positioning in APIs, generic ingredients and custom synthesis/CDMO, where higher-value products and better capacity utilisation can support future growth. Q1 also saw PAT margin expand substantially, reflecting improved profitability. Another positive is the improving outlook for custom synthesis and CDMO, which can provide longer-term growth beyond traditional API sales. Broker sentiment has also remained constructive; Citi recently reiterated a Buy view on Divi’s, highlighting its long-term growth potential.

See More
Nikita (SEBI RA)

Nikita (SEBI RA)

8 Sep • 1:03 PM · SEBI-Registered Analyst

“Why Overconfidence Can Be as Dangerous as Fear”

Fear is often discussed as a major problem in trading, but overconfidence can create equally damaging decisions. After a series of successful trades, a trader may begin to believe that the next trade is also likely to succeed. This can lead to larger positions, weaker setups and reduced attention to risk. A professional approach treats every new opportunity independently. Previous profits do not provide additional certainty about the next market movement. The same entry criteria, risk limits and execution rules should continue to apply regardless of recent performance. Overconfidence can also appear after correctly predicting a major market move. Being right once does not mean that every future prediction will be correct. Markets continuously change, and no trader can eliminate uncertainty completely. Maintaining discipline after winning trades is therefore an important part of long-term consistency. Learning: A winning streak should increase your discipline, not your willingness to take unnecessary risk.

DIVISLAB

See More
Dhwani Patel

Dhwani Patel

8 Sep • 7:49 AM · SEBI-Registered Analyst

Divi’s Laboratories Extends Its Breakout, positive Trend

DIVISLAB
is showing one of the cleaner continuation structures within the pharmaceutical and contract-manufacturing space. The broader pharma theme remains supported by global outsourcing, supply-chain diversification, rising demand for custom synthesis and renewed interest in high-quality API manufacturers, while Divi’s benefits from scale, execution quality and a strong position in complex manufacturing. On the chart, the most important development is the decisive breakout from the long consolidation zone around ₹6,600–6,800. That resistance had capped price for several months, and once it was cleared, the stock accelerated sharply and has continued making higher highs. Price is now trading near ₹9,315 and remains comfortably above the Ichimoku cloud, with the conversion and base lines also positioned positively. This indicates that both trend and momentum remain in favour of buyers. The recent pause near the highs looks more like consolidation after expansion than immediate distribution. The first area to monitor on any pullback is around ₹9,000, followed by a broader support zone near ₹8,700–8,800. As long as price continues to hold above these levels, the breakout structure remains intact and the trend continues to favour strength over mean reversion.

See More
CA Sumit Mangla

CA Sumit Mangla

7 Sep • 2:02 PM · SEBI-Registered Analyst

Morepen Labs Completes Phase-1 Capacity Expansion

MOREPENLAB
has successfully completed the first phase of its manufacturing capacity expansion programme ahead of schedule. The company’s installed reactor capacity for API and CDMO operations has increased from 535 KL to 614 KL. The early completion of this phase strengthens Morepen’s ability to support growing demand in its active pharmaceutical ingredients and contract development and manufacturing organisation businesses. The expansion forms part of a multi-phase roadmap aimed at scaling capacity to meet larger global CDMO opportunities and higher-value manufacturing requirements. By enhancing reactor capacity ahead of schedule, Morepen is better positioned to execute on existing mandates and pursue additional partnerships. The development underscores the company’s focus on operational readiness and timely infrastructure upgrades to support its growth strategy in the pharmaceutical manufacturing space. *Top stocks in the API & CDMO industry:* Laurus Labs, Divi’s Laboratories, and Solara Active Pharma Sciences.

See More

Frequently Asked Questions

What is the share price of Divi's Laboratories Ltd.?

What is the market cap of Divi's Laboratories Ltd.?

Should I buy Divi's Laboratories Ltd. stock now?

What is the 52 week high and low of Divi's Laboratories Ltd.?

Is the Divi's Laboratories Ltd. stock good to buy?

Is Divi's Laboratories Ltd. a good buy for the long term?

Is Divi's Laboratories Ltd. overvalued or undervalued?

What is the PE and PB ratio of Divi's Laboratories Ltd.?

Start Now